Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Clinical Trial Research Software Provides Range of Trial Capabilities in Unified Platform

By BiotechDaily International staff writers
Posted on 05 Aug 2013
New clinical trial software provides end-to-end study support through a single, easy-to-use interface that allows the ability to manage and run studies more effectively. It offers built-in study templates, libraries, and reports to help users create studies rapidly and manage them effectively without technical help.

Merge Healthcare. Inc. (Chicago, IL, USA), a provider of clinical systems, reported that SGS Life Science Services (Geneva, Switzerland) , a contract service organization with over 35 years’ experience in clinical research, has selected Merge’s eClinical OS to streamline data management across phase I-IV studies.

“SGS sought a comprehensive EDC solution that would still be cost-effective for our biotech and smaller pharmaceutical clients,” explained Joris De Bondt, head of EDC and data standards of clinical research at SGS Life Science Services. “More specifically, we needed a system that included interactive response and drug dispensing in addition to data capture functionality. We were pleased to find that Merge’s eClinical OS includes such a broad set of capabilities. Using one system for everything needed maximizes efficiency and improves timelines across all our studies.”

“As one of the premier global CROs in the industry, we’re very pleased to have SGS as a partner,” said Zaher El-Assi, general manager of Merge eClinical. “We find that our CRO partners benefit greatly from training and ongoing support through the Merge Certified Designer program. Our goal is to empower our CRO partners to better serve their customers by developing internal expertise to quickly build, test, and deploy trials for their organization regardless of trial complexity and size.”

“We were most impressed with the ability to tailor the system for each study depending on the features needed. The unique pay-as-you go model provides us with more cost efficiencies that we are then able to pass along to our clients,” explained Mr. De Bondt. “Another benefit was how straight-forward the system was to use. Our team was able to learn the system, build a complete trial and have the trial validated and pass user acceptance testing faster than with previous systems.”

Merge eClinical OS provides end-to-end study support through a single, easy-to-use interface allowing clients to manage and run studies more efficiently than ever before. The system works for the largest and smallest studies, has the flexibility to support trials in any phase, and captures any type of data, from any source, from any modality at any time.

Merge also provides clinical trials software, health stations, and other health data and analytics solutions that engage consumers in their personal health.

SGS Life Science Services is a contract service organization (CSO) providing clinical research, biologics characterization, biosafety, and quality control (QC) testing. SGS provides pharmaceutical companies with phase I-IV clinical trial management services encompassing clinical project management and monitoring, pharmacokinetic/pharmacodynamic (PK/PD) simulation and modeling services, data management, biostatistics, and regulatory consultancy.


Related Links:
Merge Healthcare
SGS Life Science Services


comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.